Tag: Prescription Drugs
2011 to 2017 Saw Increase in Spending on DMTs for MS
Increase in annual expenditures on MS DMTs mainly driven by increases in per-prescription costs
Intensive Systolic BP Control May Not Benefit All Older Adults
No real benefit seen for adults ≥80 years with lower cognitive function
Antipsychotic Use Safer Than No Use in Schizophrenia
No increase seen in severe morbidity, hospitalization when compared with periods of nonexposure
Gout Incidence Down With SGLT2 Inhibitors in Type 2 Diabetes
Gout incidence rate significantly reduced with SGLT2 inhibitor versus GLP-1 receptor agonist
California May Start Producing Its Own Medicines
Proposal also includes a single market for drug pricing in the state
Early Antiretroviral Therapy May Not Achieve HIV Remission in Infants
Similar proportion of infants attain, sustain viral suppression when starting <48 hours, two to 14 days after birth
Luspatercept Mitigates Anemia in Lower-Risk Myelodysplastic Syndromes
Transfusion burden reduced in patients with lower-risk myelodysplastic syndromes with ring sideroblasts
Antipsychotic Initiation Ups Risk for Head Injury, TBI in Alzheimer Disease
TBI injury risk up for quetiapine versus risperidone users
Prevalence of Buprenorphine-Waivered Prescribers Increasing
Increase seen from 2007 to 2017; growth faster in counties with higher rates of opioid-related OD deaths
CDC Data May Be Underreporting Scope of Overdose Deaths
Number of deaths in Florida 19 to 39 percent higher using Florida Medical Examiners Commission data